Introduction: Hepatic metastases develop in 85% of patients with GI neuroendocrine tumors. Liver-directed therapies allows for manageable microinvasive treatments able to improve the benefit and reduce the toxicity.
Aim(s): This study aimed to assess the feasibility, safety, efficacy and prognostic factors in patients with unresectable GI neuroendocrine liver metastases treated by liver-directed therapies including TACE and RFA.
Materials and methods: 24 patients (5 women) aged 28 to 77 years(mean age:57Y) histologically diagnosed GI NET-LM (14 cases were synchronous and 1 functioning tumor was gastrinoma )who were performed loco-regional therapies in our hospital from Jun 2004 to sep 2014 were analysed.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Lingxiao J Liu
To read results and conclusion, please login ...
Further abstracts you may be interested in